The European Commission has reportedly halted its merger investigation into Zimmer Holding’s proposed acquisition of Biomet, announcing Thursday that the regulator will need more information on the deal.
US-based orthopedic product maker Zimmer is looking to acquire Biomet for $13.4 billion, but according to the EU regulator, the merger filing lacks crucial information for the Commission to properly asses the deal. The submission for the deal was filed June 3.
Reports say the transaction would create the industry’s second-largest player behind Johnson & Johnson.
The Commission announced Thursday that the merger application was “incomplete,” causing the watchdog to scrap its initial July 9 date for merger review completion. A new date will be set following the acquisition of the requested information.
Full content: Interactive Investor
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Extends Support for Farms and Fisheries Amid Market Disruptions
May 5, 2024 by
CPI
Sony and Apollo Bid $26 Billion for Paramount Acquisition
May 5, 2024 by
CPI
Goldman Sachs Resolves Decade-Old Metal-Rigging Class Action Lawsuit
May 5, 2024 by
CPI
Italian Antitrust Ruling Puts Halt on Intesa Sanpaolo’s Fintech Ambitions
May 5, 2024 by
CPI
Google Antitrust Case: Closing Arguments Conclude
May 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI